Trial: 201910101

A Multi-Center Phase 2 Study of Combined Modality Treatment with Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS

Phase

II

Principal Investigator

Schroeder, Mark

Disease Site

Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Myeloid and Monocytic Leukemia; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov